Pharma & Healthcare

Global Neuromyelitis Optica Drug Market Research Report 2026

This report delivers a comprehensive overview of the global Neuromyelitis Optica Drug market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Neuromyelitis Optica Drug. The Neuromyelitis Optica Drug market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Neuromyelitis Optica Drug market comprehensively. Regional market sizes by Type, by Application, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Neuromyelitis Optica Drug manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Pfizer
Fresenius
Teva
Sandoz
Intas
Gyjtrs
NANG KUANG
Tianjin Kingyork
Baxter
CSL
Grifols
Octapharma
CBOP
Segment by Type
Glucocorticoids
Immunotherapies
Others
Segment by Application
Acute Attack
Remission Prophylactic Treatment
By Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia & New Zealand
Rest of Asia
Europe
Germany
France
U.K.
Italy
Ireland
Russia
Rest of Europe
Latin America
Mexico
Brazil
Argentina
Rest of Latin America
Middle East & Africa
Israel
United Arab Emirates (UAE)
Saudi Arabia
Rest of MEA
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for Neuromyelitis Optica Drug companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neuromyelitis Optica Drug Market Size Growth Rate by Type: 2021 vs 2025 vs 2032
1.2.2 Glucocorticoids
1.2.3 Immunotherapies
1.2.4 Others
1.3 Market by Application
1.3.1 Global Neuromyelitis Optica Drug Market Growth by Application: 2021 vs 2025 vs 2032
1.3.2 Acute Attack
1.3.3 Remission Prophylactic Treatment
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Neuromyelitis Optica Drug Market Perspective (2021–2032)
2.2 Global Neuromyelitis Optica Drug Growth Trends by Region
2.2.1 Global Neuromyelitis Optica Drug Market Size by Region: 2021 vs 2025 vs 2032
2.2.2 Neuromyelitis Optica Drug Historic Market Size by Region (2021–2026)
2.2.3 Neuromyelitis Optica Drug Forecasted Market Size by Region (2027–2032)
2.3 Neuromyelitis Optica Drug Market Dynamics
2.3.1 Neuromyelitis Optica Drug Industry Trends
2.3.2 Neuromyelitis Optica Drug Market Drivers
2.3.3 Neuromyelitis Optica Drug Market Challenges
2.3.4 Neuromyelitis Optica Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Neuromyelitis Optica Drug Players by Revenue
3.1.1 Global Top Neuromyelitis Optica Drug Players by Revenue (2021–2026)
3.1.2 Global Neuromyelitis Optica Drug Revenue Market Share by Players (2021–2026)
3.2 Global Top Neuromyelitis Optica Drug Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
3.3 Global Key Players Ranking by Neuromyelitis Optica Drug Revenue
3.4 Global Neuromyelitis Optica Drug Market Concentration Ratio
3.4.1 Global Neuromyelitis Optica Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neuromyelitis Optica Drug Revenue in 2025
3.5 Global Key Players of Neuromyelitis Optica Drug Head Offices and Areas Served
3.6 Global Key Players of Neuromyelitis Optica Drug, Products and Applications
3.7 Global Key Players of Neuromyelitis Optica Drug, Date of General Availability (GA)
3.8 Mergers and Acquisitions, Expansion Plans
4 Neuromyelitis Optica Drug Breakdown Data by Type
4.1 Global Neuromyelitis Optica Drug Historic Market Size by Type (2021–2026)
4.2 Global Neuromyelitis Optica Drug Forecasted Market Size by Type (2027–2032)
5 Neuromyelitis Optica Drug Breakdown Data by Application
5.1 Global Neuromyelitis Optica Drug Historic Market Size by Application (2021–2026)
5.2 Global Neuromyelitis Optica Drug Forecasted Market Size by Application (2027–2032)
6 North America
6.1 North America Neuromyelitis Optica Drug Market Size (2021–2032)
6.2 North America Neuromyelitis Optica Drug Market Growth Rate by Country: 2021 vs 2025 vs 2032
6.3 North America Neuromyelitis Optica Drug Market Size by Country (2021–2026)
6.4 North America Neuromyelitis Optica Drug Market Size by Country (2027–2032)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Neuromyelitis Optica Drug Market Size (2021–2032)
7.2 Europe Neuromyelitis Optica Drug Market Growth Rate by Country: 2021 vs 2025 vs 2032
7.3 Europe Neuromyelitis Optica Drug Market Size by Country (2021–2026)
7.4 Europe Neuromyelitis Optica Drug Market Size by Country (2027–2032)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Neuromyelitis Optica Drug Market Size (2021–2032)
8.2 Asia-Pacific Neuromyelitis Optica Drug Market Growth Rate by Region: 2021 vs 2025 vs 2032
8.3 Asia-Pacific Neuromyelitis Optica Drug Market Size by Region (2021–2026)
8.4 Asia-Pacific Neuromyelitis Optica Drug Market Size by Region (2027–2032)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Neuromyelitis Optica Drug Market Size (2021–2032)
9.2 Latin America Neuromyelitis Optica Drug Market Growth Rate by Country: 2021 vs 2025 vs 2032
9.3 Latin America Neuromyelitis Optica Drug Market Size by Country (2021–2026)
9.4 Latin America Neuromyelitis Optica Drug Market Size by Country (2027–2032)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Neuromyelitis Optica Drug Market Size (2021–2032)
10.2 Middle East & Africa Neuromyelitis Optica Drug Market Growth Rate by Country: 2021 vs 2025 vs 2032
10.3 Middle East & Africa Neuromyelitis Optica Drug Market Size by Country (2021–2026)
10.4 Middle East & Africa Neuromyelitis Optica Drug Market Size by Country (2027–2032)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Details
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Neuromyelitis Optica Drug Introduction
11.1.4 Pfizer Revenue in Neuromyelitis Optica Drug Business (2021–2026)
11.1.5 Pfizer Recent Development
11.2 Fresenius
11.2.1 Fresenius Company Details
11.2.2 Fresenius Business Overview
11.2.3 Fresenius Neuromyelitis Optica Drug Introduction
11.2.4 Fresenius Revenue in Neuromyelitis Optica Drug Business (2021–2026)
11.2.5 Fresenius Recent Development
11.3 Teva
11.3.1 Teva Company Details
11.3.2 Teva Business Overview
11.3.3 Teva Neuromyelitis Optica Drug Introduction
11.3.4 Teva Revenue in Neuromyelitis Optica Drug Business (2021–2026)
11.3.5 Teva Recent Development
11.4 Sandoz
11.4.1 Sandoz Company Details
11.4.2 Sandoz Business Overview
11.4.3 Sandoz Neuromyelitis Optica Drug Introduction
11.4.4 Sandoz Revenue in Neuromyelitis Optica Drug Business (2021–2026)
11.4.5 Sandoz Recent Development
11.5 Intas
11.5.1 Intas Company Details
11.5.2 Intas Business Overview
11.5.3 Intas Neuromyelitis Optica Drug Introduction
11.5.4 Intas Revenue in Neuromyelitis Optica Drug Business (2021–2026)
11.5.5 Intas Recent Development
11.6 Gyjtrs
11.6.1 Gyjtrs Company Details
11.6.2 Gyjtrs Business Overview
11.6.3 Gyjtrs Neuromyelitis Optica Drug Introduction
11.6.4 Gyjtrs Revenue in Neuromyelitis Optica Drug Business (2021–2026)
11.6.5 Gyjtrs Recent Development
11.7 NANG KUANG
11.7.1 NANG KUANG Company Details
11.7.2 NANG KUANG Business Overview
11.7.3 NANG KUANG Neuromyelitis Optica Drug Introduction
11.7.4 NANG KUANG Revenue in Neuromyelitis Optica Drug Business (2021–2026)
11.7.5 NANG KUANG Recent Development
11.8 Tianjin Kingyork
11.8.1 Tianjin Kingyork Company Details
11.8.2 Tianjin Kingyork Business Overview
11.8.3 Tianjin Kingyork Neuromyelitis Optica Drug Introduction
11.8.4 Tianjin Kingyork Revenue in Neuromyelitis Optica Drug Business (2021–2026)
11.8.5 Tianjin Kingyork Recent Development
11.9 Baxter
11.9.1 Baxter Company Details
11.9.2 Baxter Business Overview
11.9.3 Baxter Neuromyelitis Optica Drug Introduction
11.9.4 Baxter Revenue in Neuromyelitis Optica Drug Business (2021–2026)
11.9.5 Baxter Recent Development
11.10 CSL
11.10.1 CSL Company Details
11.10.2 CSL Business Overview
11.10.3 CSL Neuromyelitis Optica Drug Introduction
11.10.4 CSL Revenue in Neuromyelitis Optica Drug Business (2021–2026)
11.10.5 CSL Recent Development
11.11 Grifols
11.11.1 Grifols Company Details
11.11.2 Grifols Business Overview
11.11.3 Grifols Neuromyelitis Optica Drug Introduction
11.11.4 Grifols Revenue in Neuromyelitis Optica Drug Business (2021–2026)
11.11.5 Grifols Recent Development
11.12 Octapharma
11.12.1 Octapharma Company Details
11.12.2 Octapharma Business Overview
11.12.3 Octapharma Neuromyelitis Optica Drug Introduction
11.12.4 Octapharma Revenue in Neuromyelitis Optica Drug Business (2021–2026)
11.12.5 Octapharma Recent Development
11.13 CBOP
11.13.1 CBOP Company Details
11.13.2 CBOP Business Overview
11.13.3 CBOP Neuromyelitis Optica Drug Introduction
11.13.4 CBOP Revenue in Neuromyelitis Optica Drug Business (2021–2026)
11.13.5 CBOP Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Neuromyelitis Optica Drug Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
Table 2. Key Players of Glucocorticoids
Table 3. Key Players of Immunotherapies
Table 4. Key Players of Others
Table 5. Global Neuromyelitis Optica Drug Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
Table 6. Global Neuromyelitis Optica Drug Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 7. Global Neuromyelitis Optica Drug Market Size by Region (US$ Million), 2021–2026
Table 8. Global Neuromyelitis Optica Drug Market Share by Region (2021–2026)
Table 9. Global Neuromyelitis Optica Drug Forecasted Market Size by Region (US$ Million), 2027–2032
Table 10. Global Neuromyelitis Optica Drug Market Share by Region (2027–2032)
Table 11. Neuromyelitis Optica Drug Market Trends
Table 12. Neuromyelitis Optica Drug Market Drivers
Table 13. Neuromyelitis Optica Drug Market Challenges
Table 14. Neuromyelitis Optica Drug Market Restraints
Table 15. Global Neuromyelitis Optica Drug Revenue by Players (US$ Million), 2021–2026
Table 16. Global Neuromyelitis Optica Drug Market Share by Players (2021–2026)
Table 17. Global Top Neuromyelitis Optica Drug Players by Tier (Tier 1, Tier 2, and Tier 3), based on Neuromyelitis Optica Drug Revenue, 2025
Table 18. Ranking of Global Top Neuromyelitis Optica Drug Companies by Revenue (US$ Million) in 2025
Table 19. Global 5 Largest Players Market Share by Neuromyelitis Optica Drug Revenue (CR5 and HHI), 2021–2026
Table 20. Global Key Players of Neuromyelitis Optica Drug, Headquarters and Area Served
Table 21. Global Key Players of Neuromyelitis Optica Drug, Products and Applications
Table 22. Global Key Players of Neuromyelitis Optica Drug, Date of General Availability (GA)
Table 23. Mergers and Acquisitions, Expansion Plans
Table 24. Global Neuromyelitis Optica Drug Market Size by Type (US$ Million), 2021–2026
Table 25. Global Neuromyelitis Optica Drug Revenue Market Share by Type (2021–2026)
Table 26. Global Neuromyelitis Optica Drug Forecasted Market Size by Type (US$ Million), 2027–2032
Table 27. Global Neuromyelitis Optica Drug Revenue Market Share by Type (2027–2032)
Table 28. Global Neuromyelitis Optica Drug Market Size by Application (US$ Million), 2021–2026
Table 29. Global Neuromyelitis Optica Drug Revenue Market Share by Application (2021–2026)
Table 30. Global Neuromyelitis Optica Drug Forecasted Market Size by Application (US$ Million), 2027–2032
Table 31. Global Neuromyelitis Optica Drug Revenue Market Share by Application (2027–2032)
Table 32. North America Neuromyelitis Optica Drug Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 33. North America Neuromyelitis Optica Drug Market Size by Country (US$ Million), 2021–2026
Table 34. North America Neuromyelitis Optica Drug Market Size by Country (US$ Million), 2027–2032
Table 35. Europe Neuromyelitis Optica Drug Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 36. Europe Neuromyelitis Optica Drug Market Size by Country (US$ Million), 2021–2026
Table 37. Europe Neuromyelitis Optica Drug Market Size by Country (US$ Million), 2027–2032
Table 38. Asia-Pacific Neuromyelitis Optica Drug Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032
Table 39. Asia-Pacific Neuromyelitis Optica Drug Market Size by Region (US$ Million), 2021–2026
Table 40. Asia-Pacific Neuromyelitis Optica Drug Market Size by Region (US$ Million), 2027–2032
Table 41. Latin America Neuromyelitis Optica Drug Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 42. Latin America Neuromyelitis Optica Drug Market Size by Country (US$ Million), 2021–2026
Table 43. Latin America Neuromyelitis Optica Drug Market Size by Country (US$ Million), 2027–2032
Table 44. Middle East & Africa Neuromyelitis Optica Drug Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 45. Middle East & Africa Neuromyelitis Optica Drug Market Size by Country (US$ Million), 2021–2026
Table 46. Middle East & Africa Neuromyelitis Optica Drug Market Size by Country (US$ Million), 2027–2032
Table 47. Pfizer Company Details
Table 48. Pfizer Business Overview
Table 49. Pfizer Neuromyelitis Optica Drug Product
Table 50. Pfizer Revenue in Neuromyelitis Optica Drug Business (US$ Million), 2021–2026
Table 51. Pfizer Recent Development
Table 52. Fresenius Company Details
Table 53. Fresenius Business Overview
Table 54. Fresenius Neuromyelitis Optica Drug Product
Table 55. Fresenius Revenue in Neuromyelitis Optica Drug Business (US$ Million), 2021–2026
Table 56. Fresenius Recent Development
Table 57. Teva Company Details
Table 58. Teva Business Overview
Table 59. Teva Neuromyelitis Optica Drug Product
Table 60. Teva Revenue in Neuromyelitis Optica Drug Business (US$ Million), 2021–2026
Table 61. Teva Recent Development
Table 62. Sandoz Company Details
Table 63. Sandoz Business Overview
Table 64. Sandoz Neuromyelitis Optica Drug Product
Table 65. Sandoz Revenue in Neuromyelitis Optica Drug Business (US$ Million), 2021–2026
Table 66. Sandoz Recent Development
Table 67. Intas Company Details
Table 68. Intas Business Overview
Table 69. Intas Neuromyelitis Optica Drug Product
Table 70. Intas Revenue in Neuromyelitis Optica Drug Business (US$ Million), 2021–2026
Table 71. Intas Recent Development
Table 72. Gyjtrs Company Details
Table 73. Gyjtrs Business Overview
Table 74. Gyjtrs Neuromyelitis Optica Drug Product
Table 75. Gyjtrs Revenue in Neuromyelitis Optica Drug Business (US$ Million), 2021–2026
Table 76. Gyjtrs Recent Development
Table 77. NANG KUANG Company Details
Table 78. NANG KUANG Business Overview
Table 79. NANG KUANG Neuromyelitis Optica Drug Product
Table 80. NANG KUANG Revenue in Neuromyelitis Optica Drug Business (US$ Million), 2021–2026
Table 81. NANG KUANG Recent Development
Table 82. Tianjin Kingyork Company Details
Table 83. Tianjin Kingyork Business Overview
Table 84. Tianjin Kingyork Neuromyelitis Optica Drug Product
Table 85. Tianjin Kingyork Revenue in Neuromyelitis Optica Drug Business (US$ Million), 2021–2026
Table 86. Tianjin Kingyork Recent Development
Table 87. Baxter Company Details
Table 88. Baxter Business Overview
Table 89. Baxter Neuromyelitis Optica Drug Product
Table 90. Baxter Revenue in Neuromyelitis Optica Drug Business (US$ Million), 2021–2026
Table 91. Baxter Recent Development
Table 92. CSL Company Details
Table 93. CSL Business Overview
Table 94. CSL Neuromyelitis Optica Drug Product
Table 95. CSL Revenue in Neuromyelitis Optica Drug Business (US$ Million), 2021–2026
Table 96. CSL Recent Development
Table 97. Grifols Company Details
Table 98. Grifols Business Overview
Table 99. Grifols Neuromyelitis Optica Drug Product
Table 100. Grifols Revenue in Neuromyelitis Optica Drug Business (US$ Million), 2021–2026
Table 101. Grifols Recent Development
Table 102. Octapharma Company Details
Table 103. Octapharma Business Overview
Table 104. Octapharma Neuromyelitis Optica Drug Product
Table 105. Octapharma Revenue in Neuromyelitis Optica Drug Business (US$ Million), 2021–2026
Table 106. Octapharma Recent Development
Table 107. CBOP Company Details
Table 108. CBOP Business Overview
Table 109. CBOP Neuromyelitis Optica Drug Product
Table 110. CBOP Revenue in Neuromyelitis Optica Drug Business (US$ Million), 2021–2026
Table 111. CBOP Recent Development
Table 112. Research Programs/Design for This Report
Table 113. Key Data Information from Secondary Sources
Table 114. Key Data Information from Primary Sources
Table 115. Authors List of This Report


List of Figures
Figure 1. Neuromyelitis Optica Drug Picture
Figure 2. Global Neuromyelitis Optica Drug Market Size Comparison by Type (US$ Million), 2021–2032
Figure 3. Global Neuromyelitis Optica Drug Market Share by Type: 2025 vs 2032
Figure 4. Glucocorticoids Features
Figure 5. Immunotherapies Features
Figure 6. Others Features
Figure 7. Global Neuromyelitis Optica Drug Market Size by Application (US$ Million), 2021–2032
Figure 8. Global Neuromyelitis Optica Drug Market Share by Application: 2025 vs 2032
Figure 9. Acute Attack Case Studies
Figure 10. Remission Prophylactic Treatment Case Studies
Figure 11. Neuromyelitis Optica Drug Report Years Considered
Figure 12. Global Neuromyelitis Optica Drug Market Size (US$ Million), Year-over-Year: 2021–2032
Figure 13. Global Neuromyelitis Optica Drug Market Size, (US$ Million), 2021 vs 2025 vs 2032
Figure 14. Global Neuromyelitis Optica Drug Market Share by Region: 2025 vs 2032
Figure 15. Global Neuromyelitis Optica Drug Market Share by Players in 2025
Figure 16. Global Neuromyelitis Optica Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 17. The Top 10 and 5 Players Market Share by Neuromyelitis Optica Drug Revenue in 2025
Figure 18. North America Neuromyelitis Optica Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 19. North America Neuromyelitis Optica Drug Market Share by Country (2021–2032)
Figure 20. United States Neuromyelitis Optica Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 21. Canada Neuromyelitis Optica Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 22. Europe Neuromyelitis Optica Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 23. Europe Neuromyelitis Optica Drug Market Share by Country (2021–2032)
Figure 24. Germany Neuromyelitis Optica Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 25. France Neuromyelitis Optica Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 26. U.K. Neuromyelitis Optica Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 27. Italy Neuromyelitis Optica Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 28. Russia Neuromyelitis Optica Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 29. Ireland Neuromyelitis Optica Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 30. Asia-Pacific Neuromyelitis Optica Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 31. Asia-Pacific Neuromyelitis Optica Drug Market Share by Region (2021–2032)
Figure 32. China Neuromyelitis Optica Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 33. Japan Neuromyelitis Optica Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 34. South Korea Neuromyelitis Optica Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 35. Southeast Asia Neuromyelitis Optica Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 36. India Neuromyelitis Optica Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 37. Australia & New Zealand Neuromyelitis Optica Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 38. Latin America Neuromyelitis Optica Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 39. Latin America Neuromyelitis Optica Drug Market Share by Country (2021–2032)
Figure 40. Mexico Neuromyelitis Optica Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 41. Brazil Neuromyelitis Optica Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 42. Middle East & Africa Neuromyelitis Optica Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 43. Middle East & Africa Neuromyelitis Optica Drug Market Share by Country (2021–2032)
Figure 44. Israel Neuromyelitis Optica Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 45. Saudi Arabia Neuromyelitis Optica Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 46. UAE Neuromyelitis Optica Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 47. Pfizer Revenue Growth Rate in Neuromyelitis Optica Drug Business (2021–2026)
Figure 48. Fresenius Revenue Growth Rate in Neuromyelitis Optica Drug Business (2021–2026)
Figure 49. Teva Revenue Growth Rate in Neuromyelitis Optica Drug Business (2021–2026)
Figure 50. Sandoz Revenue Growth Rate in Neuromyelitis Optica Drug Business (2021–2026)
Figure 51. Intas Revenue Growth Rate in Neuromyelitis Optica Drug Business (2021–2026)
Figure 52. Gyjtrs Revenue Growth Rate in Neuromyelitis Optica Drug Business (2021–2026)
Figure 53. NANG KUANG Revenue Growth Rate in Neuromyelitis Optica Drug Business (2021–2026)
Figure 54. Tianjin Kingyork Revenue Growth Rate in Neuromyelitis Optica Drug Business (2021–2026)
Figure 55. Baxter Revenue Growth Rate in Neuromyelitis Optica Drug Business (2021–2026)
Figure 56. CSL Revenue Growth Rate in Neuromyelitis Optica Drug Business (2021–2026)
Figure 57. Grifols Revenue Growth Rate in Neuromyelitis Optica Drug Business (2021–2026)
Figure 58. Octapharma Revenue Growth Rate in Neuromyelitis Optica Drug Business (2021–2026)
Figure 59. CBOP Revenue Growth Rate in Neuromyelitis Optica Drug Business (2021–2026)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
Choose Your Edition
Add to cart

Our team would be happy to assist you with your queries.

Contact us

About us

Accurate data, The latest market trends, And deeper research directions.

Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals

Latest reports

Useful links

Our Contacts

Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China

(+86) 159 1069 5232

sales@hengceresearch.com
hengceresearch.com

Allow cookies